Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors

Valeria Famiglini, Giuseppe La Regina, Antonio Coluccia, Sveva Pelliccia, Andrea Brancale, Giovanni Maga, Emmanuele Crespan, Roger Badia, Eva Riveira-Muñoz, José A. Esté, Rosella Ferretti, Roberto Cirilli, Claudio Zamperini, Maurizio Botta, Dominique Schols, Vittorio Limongelli, Bruno Agostino, Ettore Novellino, Romano Silvestri

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

© 2014 American Chemical Society. We synthesized new indolylarylsulfone (IAS) derivatives carrying a heterocyclic tail at the indole-2-carboxamide nitrogen as potential anti-HIV/AIDS agents. Several new IASs yielded EC<inf>50</inf> values <1.0 nM against HIV-1 WT and mutant strains in MT-4 cells. The (R)-11 enantiomer proved to be exceptionally potent against the whole viral panel; in the reverse transcriptase (RT) screening assay, it was remarkably superior to NVP and EFV and comparable to ETV. The binding poses were consistent with the one previously described for the IAS non-nucleoside reverse transcriptase inhibitors. Docking studies showed that the methyl group of (R)-11 points toward the cleft created by the K103N mutation, different from the corresponding group of (S)-11. By calculating the solvent-accessible surface, we observed that the exposed area of RT in complex with (S)-11 was larger than the area of the (R)-11 complex. Compounds 6 and 16 and enantiomer (R)-11 represent novel robust lead compounds of the IAS class.
Original languageEnglish
Pages (from-to)9945-9957
JournalJournal of Medicinal Chemistry
Volume57
Issue number23
DOIs
Publication statusPublished - 11 Dec 2014

Fingerprint Dive into the research topics of 'Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors'. Together they form a unique fingerprint.

Cite this